Equity Overview
Price & Market Data
Price: $1.49
Daily Change: +$0.02 / 1.34%
Daily Range: $1.45 - $1.56
Market Cap: $6,525,170
Daily Volume: 62,216
Performance Metrics
1 Week: -2.05%
1 Month: -51.81%
3 Months: 31.46%
6 Months: -50.21%
1 Year: -89.02%
YTD: -83.07%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.